DBV Technologies And 2 Other Stocks Under $2 Insiders Are Buying
DBV Technologies And 2 Other Stocks Under $2 Insiders Are Buying
The Dow Jones index closed higher by around 50 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
道瓊斯指數週四收高約50點。當內部人士購買或出售股票時，這表明他們對公司前景的信心或擔憂。對細價股感興趣的投資者和交易者可以將此視爲他們整體投資或交易決策的一個因素。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
以下是近期一些值得注意的細價股內幕交易。欲了解更多，請查看 本辛加的內幕交易 平台。
Dalrada Financial
達爾拉達金融
- The Trade: Dalrada Financial Corporation (OTC:DFCO) Chief Executive Officer Brian Bonar acquired a total of 52,600 shares an average price of $0.22. To acquire these shares, it cost around $11,831.
- What's Happening: The company's stock fell around 16% over the past month.
- What Dalrada Financial Does: Dalrada Financial Corp is a United States-based company engaged in providing financial, insurance, benefit, and business process outsourcing products and services to companies.
- 交易：達爾拉達金融公司（場外交易代碼：DFCO）首席執行官布萊恩·博納爾 共收購了52,600股股票 平均價格爲0.22美元。收購這些股票的成本約爲11,831美元。
- 發生了什麼：該公司的股票在過去一個月中下跌了約16％。
- Dalrada Financial做什麼：Dalrada Financial Corp是一家總部位於美國的公司，致力於爲公司提供財務、保險、福利和業務流程外包產品和服務。
Research Frontiers
研究前沿
- The Trade: Research Frontiers Incorporated (NASDAQ:REFR) Director Darryl Daigle acquired a total of 1,000 shares at at an average price of $1.00. To acquire these shares, it cost around $1,000.
- What's Happening: On Nov. 2, Research Frontiers posted a narrower third-quarter loss.
- What Research Frontiers Does: Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light.
- 貿易：研究前沿公司（納斯達克股票代碼：REFR）董事達里爾·戴格爾 共收購了1,000股股票 平均價格爲1.00美元。收購這些股票的成本約爲1,000美元。
- 發生了什麼：11月2日，Research Frontiers公佈的第三季度虧損幅度較小。
- Research Frontiers做什麼：Research Frontiers Inc從事控制光流的技術和設備的開發和營銷。
Check This Out: Investor Sentiment Edges Higher As S&P 500 Briefly Breaches 5,000 Level
看看這個： 隨着標準普爾500指數短暫突破5,000水平，投資者情緒小幅走高
DBV Technologies
DBV 科技
- The Trade: DBV Technologies S.A. (NASDAQ:DBVT) Director Adora Ndu acquired a total of 1,825 shares at an average price of $0.89. The insider spent around $1,624 to buy those shares.
- What's Happening: On Nov. 10, DBV Technologies announced 2-year results from ongoing Phase 3 open-label extension to the EPITOPE trial (EPOPEX) of Viaskin peanut in toddlers.
- What DBV Technologies Does: DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin.
- 交易：DBV Technologies S.A.（納斯達克股票代碼：DBVT）董事阿多拉·恩杜 共收購了1,825股股票 平均價格爲0.89美元。知情人士花費了約1,624美元購買了這些股票。
- 發生了什麼：11月10日，DBV Technologies公佈了正在進行的針對幼兒的Viaskin花生的EPITOPE試驗（EPOPEX）的第三階段開放標籤延期的兩年結果。
- DBV Technologies的所作所爲：DBV Technologies SA是一家臨床階段的專業生物製藥公司，專注於通過開發名爲Viaskin的新型技術平台來改變免疫療法領域。
Don't forget to check out our premarket coverage here
別忘了在這裏查看我們的上市前報道
譯文內容由第三人軟體翻譯。